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Abstract: MET is located on chromosome 7q31 and is a proto-oncogene that encodes for hepatocyte growth factor (HGF) receptor, a member of the receptor tyrosine kinase (RTK) family.
HGF, also known as scatter factor (SF), is the only known ligand for MET. MET is a master
regulator of cell growth and division (mitogenesis), mobility (motogenesis), and differentiation
(morphogenesis); it plays an important role in normal development and tissue regeneration. The
HGF-MET axis is frequently dysregulated in cancer by MET gene amplification, translocation,
and mutation, or by MET or HGF protein overexpression. MET dysregulation is associated with
an increased propensity for metastatic disease and poor overall prognosis across multiple tumor
types. Targeting the dysregulated HGF-MET pathway is an area of active research; a number
of monoclonal antibodies to HGF and MET, as well as small molecule inhibitors of MET, are
under development. This review summarizes the key biological features of the HGF-MET axis,
its dysregulation in cancer, and the therapeutic agents targeting the HGF-MET axis, which are
in development.
Keywords: MET inhibitor, HGF inhibitor, cancer

Hepatocyte growth factor (HGF)-MET pathway
in normal development and tumorigenesis
Nearly 30 years ago, HGF was identified as a modulator of hepatocyte proliferation
and regeneration by three independent groups of investigators.1–3 HGF is a heterodimer
with a larger α subunit and smaller β subunit with homology to tissue plasminogen.4
HGF is secreted by cells of mesenchymal origin and binds to the MET receptor on
epithelial and endothelial cells. Scatter factor (SF), so named due to its ability to scatter
mammary epithelial cells in culture, was characterized by complementary deoxyribonucleic acid (cDNA) cloning in 1990; SF was found to be identical to HGF, with
indistinguishable ligand activity for the MET receptor.5 HGF is secreted as a precursor
polypeptide bound to heparin proteoglycans in the extracellular matrix. The inactive
HGF polypeptide is cleaved by a serine protease at sites of tissue injury and by tumor
cells/matrix into active HGF. The only known ligand for the MET receptor is HGF,
which upon binding to MET activates a downstream cascade, leading to cell survival,
division, and motility.6
Activated MET kinase undergoes autophosphorylation on tyrosine residues
(Tyr1349 and Tyr1356) in the docking domain, leading to recruitment and transduction
of downstream effectors. Activated MET phosphorylates and binds to growth factor
receptor-bound protein 2 (GRB2) and GRB2-associated binding protein 1 (GAB1),
acting as a scaffold and promoting MET interactions with proteins involved in the
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phosphoinositol 3-kinase (PI3K)-protein kinase B (Akt)
pathway, the signal transducer and activator of transcription
factor (STAT) pathway, the mitogen-activated protein kinase
(MAPK) pathway, and the nuclear factor kappa-light-chainenhancer of activated B cells (NFkB) pathway.7 All of these
pathways form an integral part of the MET-dependent cell
growth, survival, and migration-signaling cascade. During
embryogenesis, normal expression and function of HGF,
MET, and GAB1 are essential for growth and development
of hepatocytes,8 placental trophoblasts, and myoblasts. 9
After birth, activation of the HGF-MET pathway appears
to be involved in epithelial-mesenchymal transition,10
hepatic, renal, and other organ regeneration after injury, and
wound healing. Figure 1 illustrates the HGF-MET signaling
pathway.
In a subset of spontaneously transformed NIH-3T3 mouse
fibroblasts, amplification and subsequent overexpression of
the mouse MET gene was identified. This amplification was
not seen in nontransformed NIH-3T3 cells and provided the
initial proof of concept that the MET oncogene could act as

a transforming factor.11 Subsequently, MET ribonucleic acid
(RNA) and protein overexpression was observed in multiple
epithelial and mesenchymal tumor cell lines, including
breast, thyroid, liver, and kidney cancers.12 Transgenic mice
with forced overexpression of HGF were noted to develop
multiple epithelial and mesenchymal tumors. This diverse
tumorigenesis was associated with MET phosphorylation and
autocrine activation. Tumors arising in the tissues of these
transgenic mice exhibited morphologic and developmental
abnormalities, establishing the role of the HGF-MET pathway in tumorigenesis.13

HGF and MET dysregulation
in cancer
In human malignancies, the HGF-MET axis is dysregulated
by a number of mechanisms, providing tumor cells with
the ability to proliferate and disseminate. The MET gene
is activated by point mutations in small-cell lung cancer
(SCLC)14 and renal papillary carcinomas.15 MET protein is
overexpressed in melanoma and musculoskeletal tumors.16
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Figure 1 HGF-MET signaling pathway.
Abbreviations: HGF, hepatocyte growth factor; ERK, extracellular signal-regulated kinase; STAT, signal transducer and activator of transcription factor; GRB2, growth
factor receptor-bound protein 2; GAB1, GRB2-associated binding protein 1; PLC, phospholipase C; PI3K, phosphoinositol 3-kinase; Akt, protein kinase B; mTOR, mammalian
target of rapamycin.
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Fusion of MET with translocated promoter region (TPR) in
gastric carcinoma leads to MET overexpression.17–19 Aberrant HGF expression leading to autocrine activation of MET
occurs in nearly half of acute myeloid leukemia cell lines,
and depletion of HGF or MET leads to inhibition of growth
and apoptosis.20 Transgenic mice overexpressing HGF have
increased MET expression in tumor cells, providing them
with a selective growth advantage; overexpression of HGF in
tissues is associated with increased incidence of epithelial and
mesenchymal tumors.13 In an elegant study, Lorenzato et al
noted that activating somatic MET mutations were infrequent
in primary tumors but commonly present at metastatic sites,
suggesting that MET mutations are associated with progression rather than initiation of tumorigenesis.21 In colorectal
tumors, MET amplification is associated with advanced
stages and development of hepatic metastatic disease; gene
amplification was observed in 2% (3/177) of localized primary cancers, 9% (6/70) of cancers with distant metastases
(P,0.02), and 18% (25/147) of liver metastases (P,0.01).22
Thus, alterations in MET and/or HGF are frequently observed
in a wide range of cancers, and their presence appears to
confer an increased propensity for a more aggressive clinical
behavior manifested by invasion and metastasis.
Overexpression and upregulation of the HGF-MET pathway has been shown to be an important escape mechanism
for tumor cells to develop resistance to inhibition of the
epidermal growth factor receptor (EGFR), RAS-RAF-MEK,
and Akt–mTOR (mammalian target of rapamycin) pathways.
In a subset (22%) of non-small-cell lung cancers (NSCLC)
with activating mutations of the EGFR gene, MET amplification is associated with gefitinib resistance by promoting
human epidermal growth factor receptor (HER)-3-mediated
activation of PI3K.23 Overexpression of HGF followed by
MET phosphorylation in NSCLCs with EGFR-activating
mutations reactivates the PI3K-Akt signaling pathway and
leads to gefitinib resistance.24 Similarly, resistance to RAS
inhibitors is mediated by upregulation and secretion of
HGF by the tumor microenvironment.25 MET activation was
noted to mediate resistance to HER2 inhibition by lapatinib
in HER2-amplified gastric cancer cells. 26 In esophageal
squamous cell carcinoma, secretion of HGF by fibroblasts
is associated with a highly invasive phenotype and early
disease progression.27 MET amplification is associated with a
highly aggressive phenotype in a subset of gastro-esophageal
adenocarcinomas.28 TP53 mutations or p53 deficiency is
associated with MET dysregulation and promotes tumor
cell mobility and invasion.29 Alterations in the HGF-MET
axis can lead to development of resistance to inhibition
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of a number of different pathways; combining HGF/MET
inhibition with targeted EGFR, MEK, or PI3K inhibitors
would appear to represent a rational approach to treating
these resistant tumors.

Targeting the HGF-MET axis
Currently, a number of strategies targeting the HGF-MET
pathway are in development. These approaches include the
use of small molecule MET tyrosine kinase inhibitors (TKI),
anti-HGF neutralizing antibodies, and anti-MET neutralizing antibodies. Each of these approaches will be reviewed
below. The molecular sites of action for agents targeting the
HGF-MET pathway are shown in Figure 2. Table 1 summarizes the target receptors, half-life, and characteristics
of HGF-MET inhibitors. The development of a number
of these agents has advanced to evaluation for efficacy in
Phase II and Phase III clinical trials (Table 2). A timeline of
significant pathways involving the HGF-MET axis and clinical development of agents targeting the HGF-MET pathway
is shown in Figure 3.

Adenosine triphosphate (ATP)competitive MET kinase inhibitors
Foretinib
Foretinib was developed as a small molecular inhibitor
of MET and vascular endothelial growth factor (VEGF)
receptor 2 (VEGFR-2/kinase insert domain receptor
[KDR]) with additional activity against RON, KIT, fmsrelated tyrosine kinase (FLT)-1, FLT-3, platelet-derived
growth factor receptor (PDGFR)-α, PDGFR-β, fibroblast
growth factor receptor (FGFR), EGFR, and tyrosine kinase
with immunoglobulin-like and EGF-like domains (TIE)-2.
Foretinib inhibits MET at a half maximal inhibitory
concentration (IC50) of 0.4 nmol/L; subsequently, it also
inhibits HGF-mediated MET phosphorylation, migration,
and invasion of MET-amplified human gastric cancer cell
lines. In a mouse model with lung metastases, oral foretinib
produced a significant dose-dependent reduction in both
size and number of lung metastases, which led to its further
development.30
In the initial Phase I trial of foretinib in patients with
metastatic or unresectable solid tumors, 40 patients were
enrolled in eight dose cohorts. All patients received foretinib
for 5 days orally every 14 days. The maximum tolerated
dose (MTD) was 3.6 mg/kg and dose limiting toxicities
included aspartate aminotransferase and lipase elevations.
Responses were seen in two patients with papillary renal cell
carcinoma and one patient with medullary thyroid carcinoma.
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Figure 2 HGF-MET inhibitors and potential sites of action.
Abbreviations: HGF, hepatocyte growth factor; ATP, adenosine triphosphate; PSI, plexins-semaphorins-integrins; IPT, immunoglobulin-plexin-transcription.

The recommended Phase II dose (RP2D) of foretinib was
determined to be 240 mg daily for 5 days every 14 days.31 The
half-life for foretinib was determined to be approximately
40 hours, and no pharmacokinetic differences were observed
based on age, sex, or body weight.31

In a Phase II study of foretinib in patients with papillary
renal cell carcinoma, 74 patients were enrolled into two
cohorts comparing daily to intermittent foretinib. A total of
37 patients in cohort A received 240 mg foretinib on days
1–5 every 14 days, while 37 patients in cohort B received

Table 1 Summary of MET-targeted agents, target receptors, maximal tolerated dose, and half-life for HGF and MET inhibitors
Agent

Company

Target

MTD

Half-life

References

Foretinib (XL-880)

GlaxoSmithKline

3.6 mg/kg

40 hours

31

Cabozantinib (XL-184)
Crizotinib
Tivantinib (ARQ-197)

Exelixis
Pfizer
ArQule

MET, RON, KIT, FLT-1, FLT-3, PDGFR-α,
PDGFR-β, FGFR, EGFR, TIE-2
MET, RET, TIE-2, VEGFR1-3, Kit, FLT-3
MET, ALK
MET
Cytotoxic activity

80–90 hours
42 hours
3.2–6.1 hours

58

Rilotumumab (AMG102)

Amgen

Human HGF

14.5–22 days

73

Ficlatuzumab (AV-299)

Aveo

Human HGF

15 days

79

Onartuzumab (MetMab)

Genentech

Human MET

175 mg daily
250 mg twice daily
360 mg twice per day dose
(crystalline formulation)
300 mg twice per day
(amorphous formulation)
Not reached
Max dose, 20 mg/kg
Not reached
Max dose, 20 mg/kg
Not reached

48–50

11 days

Abbreviations: MTD, maximum tolerated dose; HGF, hepatocyte growth factor; FLT, fms-related tyrosine kinase; PDGFR, platelet-derived growth factor receptor; FGFR,
fibroblast growth factor; EGFR, epidermal growth factor receptor; TIE-2, tyrosine kinase with immunoglobulin-like and EGF-like domains; VEGFR, vascular endothelial growth
factor receptor; ALK, anaplastic lymphoma kinase.
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Phase II randomized
discontinuation trial

Phase III randomized
double-blind placebocontrolled trial

Castrate resistant
prostate cancer

Medullary thyroid
cancer

Cabozantinib
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Recurrent
Glioblastoma

Phase II study with two
doses of rilotumumab
10 and 20 mg/kg

Phase II open-label two
doses of rilotumumab
10 and 20 mg/kg

Randomized double-blind
placebo-controlled
Phase II trial

Advanced
hepatocellular
carcinoma

Advanced
metastatic renal
cell carcinoma

Phase II single arm open-label

MiT tumors

Rilotumumab

Phase II single arm open-label

Relapsed
refractory germ
cell tumors

Tivantinib

Phase I open-label study

ALK-rearranged
NSCLC

Crizotinib

Phase II open-label

Papillary renal
cell carcinoma

Foretinib

Design

Disease

Agent

Table 2 Results of key Phase II/III trials with HGF-MET inhibitors

Median PFS 1 month
12 week-PFS 21%
Median OS, 6 months
Stable disease, 20% patients
No objective CR or PR
Partial response, 2%
SD, 60%
Median PFS, 3.6 months (overall)
Time to progression, 1.6 months versus
placebo (1.4 months) HR, 0.64
MET high tumors: 2.7 months versus
1.4 months PFS, P,0.03
65% in tivantinib arm
72% in placebo arm
One confirmed PR
SD, 3%
One confirmed PR, 10 patients
(16%) had SD $32 weeks
Median PFS, 3.7 months with 10 mg/kg and
2 months with 20 mg/kg
ORR, 0%
PFS, 4.1 weeks 10 mg/kg and 4.3 weeks 20 mg/kg
OS, 6.5 weeks 10 mg/kg and 5.4 weeks 20 mg/kg

ORR, 57%, 6 month-PFS, 72%

Median PFS (patients with SD at 12 weeks),
23.9 weeks versus 5.9 weeks in placebo arm.
Improvement in bone scans 68% (CR 12%,
PR 56%)
67% patients reported improvement
in bone pain
Median PFS, 11.2 months for cabozantinib
and 4.2 months for placebo (P,0.0001)
ORR of 28% versus 0% for the placebo arm

ORR, 13.5%,
Median PFS, 9.3 months
Median OS, not reached

Results

Fatigue
Headache
Peripheral edema

Edema
Fatigue
Nausea
Anorexia

Neutropenia
Anemia
Fatigue

Anemia
Neutropenia

Fatigue
Hypertension
Skin rash
Dehydration
Pulmonary embolism
Vomiting
Diarrhea
Skin rash
Fatigue
Hypocalcemia
Hypertension
Nausea
Vomiting
AST, ALT elevations
Pneumonia
Syncope

Hypertension
Fatigue
Diarrhea

Adverse events

Plasma HGF increased 12-fold
Soluble cMET increased 1.17-fold
after treatment with rilotumumab

Baseline plasma HGF and soluble
MET levels did not correlate
as measure of efficacy

High expression of MET by IHC
($2+ in $50% tumor cells)

Baseline MET expression

EML4-ALK translocation analyzed
by FISH and RT-PCR
MET amplification analyzed by FISH

RET and RAS mutation were
predictive of response to cabozantinib

31

Germline MET (gMET) mutation
predictive of response, 50% ORR in
gMET mutation positive patients versus
9% in gMET mutation-negative patients
None
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Abbreviations: ORR, overall response rate; PFS, progression free survival; OS, overall survival; SD, stable disease; PR, partial response; CR, complete response; ALK, anaplastic lymphoma kinase; NSCLC, non-small-cell lung cancer;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; RT-PCR, reverse transcription polymerase chain reaction; MiT, microphthalmia transcription factor-associated tumors; IHC, immunohistochemistry; HGF, hepatocyte growth
factor; FISH, fluorescence in situ hybridization; EML4, echinoderm microtubule-associated protein-like 4.

86
High expression of MET by IHC
($2+ in $50% tumor cells)
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Phase II onartuzumab combined
with erlotinib versus erlotinib
with placebo

Fatigue
Peripheral edema
Rash
Diarrhea
Nausea

81
High stromal HGF levels associated
with improved survival
Peripheral edema
Paronychia
Skin rash

ORR for combination 43% versus gefitinib alone
40%. Median PFS 5.6 months in the combination
arm versus 4.7 months in the gefitinib
arm (P=0.47)
In MET-IHC positive patients, PFS 2.9 months
versus 1.5 months and median OS 12.6 versus
3.8 months

77
Soluble MET levels increased in all
treatment arms. Total HGF levels
increased in the rilotumumab arms
Peripheral edema
Fatigue
Median OS 12.2 months versus 11.1 months
and Median PFS 3 months versus 2.9 months
for combined rilotumumab arms versus
mitoxantrone alone arm respectively

Phase II rilotumumab 15 mg/kg
every 2 weeks or 7.5 mg/kg
every 2 weeks or placebo
in 1:1:1 manner in combination
to mitoxantrone 12 mg/m2
Phase II ficlatuzumab with
gefitinib compared to gefitinib
alone
Castrate
refractory
prostate
carcinoma

Agent

Table 2 (Continued)

Biomarkers
Adverse events
Results
Design
Disease

Reference
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80 mg daily foretinib. The overall response rate was 13.5%
and median progression-free survival was 9.3 months. Five
of ten patients with a germline MET mutation responded to
foretinib, while five of 57 patients without germline MET
mutation responded to foretinib. The most common side
effects of this agent were fatigue, hypertension, and gastrointestinal (GI) toxicity.32,33 This study is unique as the authors
clearly stratified patients based on germline or acquired MET
mutations, and they noted that germline MET mutations
were a stronger predictive marker of response to foretinib
compared to acquired MET mutations.31,32
Seventy-four patients were enrolled in a Phase II study of
foretinib in patients with metastatic gastric adenocarcinoma.
Stable disease was seen in ten of 49 patients on intermittent dosing (240 mg/day, for 5 days, every 2 weeks) and in
five of 25 patients on continuous dosing daily (80 mg/day).
Median duration of stable disease was 3.2 months, and the
study failed to meet its primary endpoint of an objective
response rate (ORR) .25%. Of 67 patients with tumor
samples, three had MET amplification, one of whom had
disease stabilization.34

PHA-665752
PHA-665752 is an ATP-competitive small-molecule inhibitor of the MET kinase with additional activity against RON
and VEGF2. In gastric carcinoma mouse-xenograft models,
PHA-665752 inhibited MET phosphorylation and tumor
growth.35 Treatment with PHA-665752 induced apoptosis in
five of five gastric cancer cell lines with MET amplification
but none of twelve cell lines without MET amplification.36
The addition of PHA-665752 to gefitinib, an EGFR TKI,
reversed acquired resistance to gefitinib in lung cancer cell
lines with MET amplification.23

BAY-853474
BAY-853474 is a selective, potent, oral small-molecule
inhibitor of the MET kinase. BAY-853474 inhibits MET
autophosphorylation in vitro and inhibits proliferation and
growth of MET-dependent tumor xenograft models in vivo.37
BAY-853474 use was associated with reduced tumor burden in glioblastoma, NSCLC, and gastric cancer xenograft
models. The inhibition of MET phosphorylation was dosedependent, and soluble plasma biomarkers HGF, VEGF,
interleukin-8, and MET-ectodomain predicted response to
treatment.38

MK-2461
MK-2461 is an inhibitor of MET with additional activity
against RON, FLT-1, FGFR, PDGFR, and other receptor
OncoTargets and Therapy 2014:7
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1989: (i) HGF cloned
(ii) MET has tyrosine kinase activity

1991: HGF-MET interaction described
1991: elevated MET protein
levels detected in carcinomas

6–1990
198

1987: (i) Full length MET cloned
(ii) Scatter factor isolated

199

1994: MET mediates mesenchymal
to epithelial cell conversion

1–
19
9

5
1995: MET amplification and
overexpression associated with
progression of colorectal cancer

1980
–19
85

1984: (i) MET-tpr chromosomal
rearrangement identified from human
osteosarcoma cell line
(ii) HGF identified as
modulator of hepatocyte
proliferation and regeneration

1995: Role of HGF in liver
development described

1996–2000

Timeline of the key basic science and
clinical events involving the HGF-MET pathway
2013: Epigenetic link between
MLL and MET described in
hepatocellular cancer

–pr

ese
nt

2012: HGF secretion mediates
innate resistance to RAF inhibition

2011

2013: onartuzumab design and
mechanism of action described

1997: papillary RCCs
noted to have activating
MET mutations

2012: cabozantinib FDA approved for
treatment of medullary thyroid cancer

20

01

00
–2

5

2001: GAB1 regulates HGF-MET
signaling to promote DNA repair
and reduced apoptosis

2006
–2010
2009: activity of foratinib
described in pre-clinical
tumor models

2007: MET amplification
promotes resistance to
gefitinib in lung cancer

Figure 3 A timeline of important discoveries related to the HGF-MET pathway. Black represents basic science discoveries and red represents clinical/translational discoveries.
Note: Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer:
rationale and progress. Nat Rev Cancer. 2012;12(2): 89–103.101 Copyright © 2012.
Abbreviations: HGF, hepatocyte growth factor; SF, scatter factor; GRB2, growth factor receptor-bound protein 2; GAB1, GRB2-associated binding protein 1; RCC, renal
cell carcinoma; DNA, deoxyribonucleic acid; FDA, Food and Drug Administration.

tyrosine kinases. In MET-amplified human GTL16 gastric
cancer cell lines and a murine xenograft model of METdependent gastric cancer, oral MK-2461 inhibited MET signaling and cell growth.39 Genomic amplification of MET and
constitutive activation of MET, FGFR2, or PDGFR2 were
noted to be predictive of response to MK-2461.39

AMG-458
AMG-458 is a potent inhibitor of the MET, VEGFR-2, and
insulin-like growth factor 1 receptor signaling pathways.40
It significantly inhibited tumor growth in the NIH-3T3 cells
transfected with TPR-MET, leading to constitutive activation of MET and U-87 MG human glioblastoma xenograft
models.41 There is currently no clinical trial information
available for AMG-458.

PF-04217903
PF-04217903 showed excellent in vitro activity against
the MET-amplified human GTL16 gastric carcinoma and
H1993 NSCLC cell lines. PF-04217903 partially inhibited
OncoTargets and Therapy 2014:7

proliferation in U-87 MG human glioblastoma cells and
two colon cancer cell lines (SW620, HT29). PF-04217903
inhibited MET phosphorylation and tumor proliferation in
both a GTL16 xenograft athymic mouse model with MET
amplification and in a U-87 MG human glioblastoma xenograft model with an activated HGF-MET autocrine loop.42,43
A Phase I study of PF-04217903 in advanced cancer was
terminated by Pfizer in early 2012.

Non-ATP-competitive MET
kinase inhibitors
Tivantinib
Tivantinib (ARQ 197) is currently undergoing Phase II
clinical development based upon preclinical cytotoxic
activity and ATP non-competitive inhibition of MET with a
minimal IC50 of 0.1 µM44 by in vitro assay of recombinant
kinase protein. Tivantinib binds to a hydrophobic cleft in the
kinase domain, stabilizing the inactive conformation and
inhibiting MET autophosphorylation.45 Tivantinib is orally
submit your manuscript | www.dovepress.com
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bioavailable, and it is metabolized by the liver cytochrome
P450 (CYP) CYP2C19, and to a lesser extent by CYP3A4.
Polymorphisms in CYP2C19 (CYP2C19*2 and CYP2C19*3)
have been identified that are associated with decreased metabolism of tivantinib, resulting in significantly increased drug
exposure.46 These polymorphisms are most commonly seen
in Asians (35% allele frequency), but also occur in AfricanAmericans (17%) and Caucasians (15%).47
In vitro, tivantinib induced caspase-dependent apoptosis
in MET-expressing human cancer cell lines, including the
HT29 (colon adenocarcinoma), MKN-45 (gastric cancer),
and MDA-MB-231 (breast cancer) cell lines; this small
molecule demonstrated antitumor activity in a wide range
of human cancer xenograft models.48
The clinical pharmacology and safety profile of tivantinib have been investigated in several Phase I studies.48–50
The main dose-limiting toxicities have been leukopenia,
neutropenia, thrombocytopenia, vomiting, and dehydration.
At a dose of 400 mg daily, febrile neutropenia was
observed in two subjects, one of whom also experienced
grade 3 mucositis, palmar-plantar erythrodysesthesia, and
hypokalemia.50 All toxicities were reversible upon discontinuation of tivantinib. Drug treatment was associated with
a decrease in phosphorylated MET, significant decreases in
total MET and phosphorylated focal adhesion kinase, and
a significant increase in the level of apoptosis, as measured
by a terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay.50 The RP2D for tivantinib was
established as 300 mg twice daily of the amorphous formulation, which is equivalent to 360 mg twice daily of the
crystalline formulation.
In a Phase II study, 47 patients with advanced micro
phthalmia transcription factor (MITF)-associated tumors
(MiT) were treated with 360 mg twice daily tivantinib.51
The study concluded that tivantinib was safe and tolerable in
patients with MiT tumors, but antitumor activity was relatively
modest, with a partial response in one clear cell sarcoma
patient (2%) and stable disease in 28 patients (60%).51
In a randomized, controlled Phase II study, the combination of tivantinib with erlotinib, an EGFR TKI, showed
a trend towards improved progression-free survival (PFS)
and overall survival (OS) compared with placebo with
erlotinib; these results were found in a subset of patients
with non-squamous histology, as well as in patients with
wild-type EGFR. Interestingly, there was a significant
benefit in PFS and OS in all 15 patients with mutated
KRAS. Although the study did not meet its primary endpoint, evidence of activity was demonstrated, particularly
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among patients with KRAS mutations.52 MARQUEE was
a randomized, double-blind, controlled study evaluating
tivantinib versus placebo, in combination with erlotinib.
Patients in the study had locally advanced or metastatic,
non-squamous NSCLC, and had received prior treatment.
However, the study was stopped early; at the planned
interim analysis, there was no improvement in overall
survival, the primary study endpoint. The combination
of erlotinib with tivantinib demonstrated a statistically
significant improvement in PFS, with no safety concerns
in the intent-to-treat population.53
Two recent preclinical studies have called into question
the mechanism of tivantinib action. A series of experiments
demonstrated that the cytotoxic effect of tivantinib on cell
lines was independent of MET genetic status (wild-type,
amplified, and/or kinase-deleted).54,55 Both studies observed
that tivantinib caused G2 arrest, in sharp contrast to other
MET inhibitors, which cause arrest at the G1 checkpoint.
Both studies observed alterations in microtubule dynamics;
in one study, tivantinib was noted to stabilize microtubules,
while the other report observed that tivantinib destabilized
microtubules. The potential implications for further clinical
development of tivantinib as a MET inhibitor are discussed
in a recent review.56

Multitargeted inhibitors of MET
and other kinases
Cabozantinib
Cabozantinib is an oral small molecule inhibitor of RET,
MET, and VEGF-2, with additional activity against VEGF-1,
VEGF-3, KIT, and FLT-3. 57 Eighty-five patients with
advanced solid malignancies, including an expansion cohort
of 37 patients with medullary thyroid cancer (MTC), were
enrolled in a Phase I dose-escalation study of oral cabozantinib. The MTD for cabozantinib was 175 mg, and dose-limiting toxicities included palmar-plantar erythrodysesthesia,
mucositis, aspartate aminotransferase, alanine transaminase,
and lipase elevations. Ten of 35 evaluable patients with
MTC had a partial response; an additional 15 patients with
MTC had stable disease for at least 6 months. Activating
RET mutations were seen in 81% of patients with MTC and
the presence of these mutations appeared to correlate with
response to cabozantinib.58 In a Phase III EXAM study,
330 patients with locally advanced or metastatic MTC were
assigned in a 2:1 ratio to receive cabozantinib 160 mg daily
or placebo, respectively. Median progression-free survival,
the primary endpoint, was 11.2 months for cabozantinib
and 4.2 months for placebo (P,0.0001), with an ORR of
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28% versus 0% for the placebo arm.59 Common grade 3 or
greater adverse events associated with cabozantinib were
diarrhea (15.9% versus 1.8%), palmar-plantar erythrodysesthesia (12.6% versus 0%), fatigue (9.3% versus 2.8%),
hypocalcemia (9.3% versus 0%), and hypertension (7.9%
versus 0%).59
Based on these results, in late 2012 cabozantinib was
approved by the US Food and Drug Administration (FDA) for
the treatment of MTC. In the EXAM study, patients with RET
mutations had a significantly longer median PFS (60 weeks)
compared to RET mutation-negative patients (25 weeks).
In the RET mutation-negative subgroup, patients with RAS
mutations had a median PFS of 47 weeks, accounting for
most of the benefit observed in this subgroup of patients.59
Thus, RET and RAS mutations in MTC are predictive of
response to cabozantinib.
One hundred and seventy one men with castrate refractory
prostate adenocarcinoma were enrolled in a Phase II randomized discontinuation trial with cabozantinib. The patients
received 100 mg of cabozantinib for a 12-week run-in period,
followed by randomization of patients with stable disease to
cabozantinib or placebo. Due to the efficacy of cabozantinib,
the randomization was halted early. The ORR at 12 weeks,
a co-primary endpoint, was 5%, while 75% of patients had
stable disease. In 31 patients with stable disease at 12 weeks
who were randomly assigned to cabozantinib or placebo, the
median progression free survival was 23.9 months with cabozantinib and 5.9 months with placebo, resulting in a hazard
ratio of 0.12. The most common dose limiting toxicities were
fatigue, hypertension, and hand-foot syndrome.60
Cabozantinib has a black-box warning for gastrointestinal
perforations (3%), fistula formation (1%), and severe hemorrhage, which occurred in 3% of patients in the EXAM trial.
Additional side effects include venous and arterial thrombosis, hypertension, and palmo-plantar erythrodysesthesia.
Cabozantinib is highly protein-bound (99.7%) and has a
long half-life of approximately 55 hours. Grapefruit juice
and other grapefruit products can inhibit CYP enzymes and
thus should be avoided with cabozantinib. A high-fat meal
increased cabozantinib Cmax by 41% and area under curve
by 57%; patients are thus recommended to not eat from 2
hours before until 1 hour after cabozantinib use. Concomitant ketoconazole use (a CYP inhibitor) in healthy subjects
increased single-dose cabozantinib exposure by 38%, while
rifampin use (a CYP inducer) reduced single-dose cabozantinib exposure by 77%. Thus coadministration of strong
CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, atazanavir, ritonavir) or CYP3A4
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inducers (phenytoin, dexamethasone, carbamazepine,
rifampin, phenobarbital, St John’s Wort) should be avoided.
Presently, there is limited data for cabozantinib use in
hepatic impairment, and it should be avoided in patients
with moderate to severe impairment. No dose adjustment is
required for cabozantinib in patients with mild or moderate
renal insufficiency.61 Cabozantinib is under investigation
in multiple other tumor types and has shown preliminary
activity in metastatic breast cancer,62 melanoma,63 hepatocellular carcinoma,64 renal cell carcinoma,65 NSCLC,66 ovarian
cancer,67 and urothelial carcinoma.68

Crizotinib
Crizotinib is a small molecule inhibitor of the anaplastic
lymphoma kinase (ALK) with additional activity against
the MET, ROS, and RON receptors at clinically relevant
doses. After evaluation of a panel of more than 120 kinases
in biochemical and phosphorylation assays, crizotinib was
identified to be nearly 20-fold more selective for both ALK
and MET than other kinases.69 Based on the results of an
open-label, two-part Phase I study in 82 patients, crizotinib
was approved for use in ALK-rearranged advanced NSCLC.
The overall response rate was 57% (46 partial and one complete response in 82 patients) with crizotinib use in this select
group of patients with ALK rearrangements.70 Crizotinib was
also noted to be active in patients with NSCLC with MET
amplification but no ALK rearrangements and in patients with
MET-amplified esophagogastric adenocarcinoma.28,71

Anti-HGF monoclonal antibodies
Rilotumumab
Rilotumumab (AMG 102) is a fully human anti-HGF neutralizing immunoglobulin G subclass 2 (IgG2) monoclonal
antibody. In preclinical tests, a combination of rilotumumab
and temozolomide, an oral cytotoxic alkylating agent, displayed growth inhibitory effects in a human glioblastoma cell
line U-87 MG. In xenograft models, combining rilotumumab
with temozolomide or docetaxel (a microtubule inhibitor,
with cytotoxic activity) induced significant tumor growth
inhibition compared to either agent alone.72 In Phase I studies, rilotumumab demonstrated linear kinetics with a mean
half-life of 18 days. It was well-tolerated at the maximum
planned dose of 20 mg/kg.73
In the Phase I clinical trial with rilotumumab, 40 patients
with refractory advanced solid malignancies were enrolled in
six sequential dose-escalation cohorts and one dose expansion
cohort. In the dose-escalation cohort, patients were administered doses of 0.5, 1, 3, 5, 10, or 20 mg/kg every 2 weeks
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until side-effects or disease progression were observed. Nine
additional patients received rilotumumab at 20 mg/kg in the
dose expansion cohort. Rilotumumab was well-tolerated with
fatigue (13%), anorexia (8%), constipation (8%), and nausea
(8%) being the most commonly observed toxicities. Sixteen
of 23 evaluable patients (70%) had stable disease with PFS
ranging from 7.9 to 40 weeks, with no actual responses.73 A
Phase Ib study in patients with advanced solid malignancies
combined rilotumumab with bevacizumab, a humanized
VEGF-A monoclonal antibody (12 patients), or motesanib,
a VEGF, PDGFR, and stem cell factor receptor inhibitor
(2 patients). The patients were sequentially enrolled into four
cohorts receiving 3, 10, or 20 mg/kg rilotumumab with 10 mg/
kg of bevacizumab, or 3 mg/kg of rilotumumab intravenous
every 2 weeks with 75 mg of oral daily motesanib. Enrollment
into the motesanib arm was suspended early due to concern
over cholecystitis caused by motesanib. Fatigue (72%), nausea (58%), constipation (42%), and peripheral edema (42%)
were the most common treatment-related side effects. Eight
of ten patients had reductions in the size of their tumors, with
four patients demonstrating stable disease at week 24 after
administration, and PFS ranged from 8–122 weeks.74
A single arm, open-label, two-stage Phase II study enrolled
61 patients with advanced or metastatic renal cell carcinoma,
with 40 patients receiving rilotumumab 10 mg/kg every 2
weeks, and 21 patients receiving the 20 mg/kg dose. The
median PFS was 3.7 months at 10 mg/kg of rilotumumab and
2 months at the 20 mg/kg dose; one patient with a confirmed
partial response remained on maintenance therapy for 2.5
years. Peripheral edema (46%), fatigue (38%), and nausea
(28%) were the most common side effects associated with
rilotumumab.75 In patients with relapsed or recurrent glioblastoma, 40 patients received rilotumumab 10 mg/kg every
2 weeks while 20 patients received rilotumumab at a dose of
20 mg/kg every 2 weeks as a part of a Phase II clinical trial.
There were no objective responses based on central assessment, and median OS and PFS were 6.5 months and 4.1 weeks,
respectively, in the 10 mg/kg dose cohort, and 5.4 months and
4.3 weeks in the 20 mg/kg dose cohort, respectively. Prior
bevacizumab treatment had no effect on the study endpoints.
Fatigue (38%), headache (33%), and peripheral edema (23%)
were the most common side effects.76
A double-blind Phase II randomized study was performed
in patients with metastatic castrate-resistant prostate adenocarcinoma and who had progressed on prior taxane therapy.
A total of 144 patients were assigned to receive rilotumumab
15 mg/kg every 2 weeks, 7.5 mg/kg every 2 weeks, or placebo
in 1:1:1 manner in combination with mitoxantrone 12 mg/m2
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with prednisone. Median OS was 12.2 months in the combined rilotumumab arms versus 11.1 months in the placebo
arm, and median PFS was 3 months compared to 2.9 months
in the placebo arm. The combined rilotumumab arms demonstrated a higher number of patients with peripheral edema
(24%) compared to the placebo arm (8%).77 A Phase III trial
(RILOMET-1, NCT01697072)78 of epirubicin, cisplatin, and
capecitabine (ECX) combined with rilotumumab or placebo
for untreated, advanced, MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma is currently ongoing.

Ficlatuzumab
Ficlatuzumab (AV-299) is a humanized monoclonal antiHGF IgG1 antibody that binds to HGF, thereby inhibiting
the HGF-MET interaction. In a Phase I study, 24 patients
with solid malignancies were treated with single agent
ficlatuzumab at 2, 5, 10, and 20 mg/kg, respectively, every
2 weeks, while 13 patients received the combination of
ficlatuzumab 20 mg/kg every 2 weeks and erlotinib 150 mg
daily. Grade 3 mucositis was seen in one patient on singleagent ficlatuzumab. Rash and diarrhea were common adverse
events seen with combination therapy.79 The half-life of
single-agent ficlatuzumab was observed to be approximately
15 days, and no MTD was determined. Ficlatuzumab therapy
was associated with elevated serum HGF levels but no
changes in serum soluble-MET levels.79
A Phase Ib study combined gefitinib 250 mg daily with two
dose levels of ficlatuzumab (10 and 20 mg/kg every 2 weeks)
in Asian patients with unresectable NSCLC. Of the 15 patients
enrolled in the study, none had dose-limiting toxicities, while
common adverse events included cough, rash, poor appetite,
and diarrhea. At the 20 mg/kg dose, five patients had a partial
response and four had stable disease at 12 weeks of treatment.80
A multicenter, randomized open-label Phase II study evaluated a
combination of ficlatuzumab with gefitinib versus gefitinib alone
in 188 patients of Asian ethnicity with stage IIIB or stage IV
NSCLC. The overall response rate was comparable for the combination (43%) and the gefitinib alone arms (40%). Median PFS
was 5.6 months in the ficlatuzumab plus gefitinib arm compared
to 4.7 months in the gefitinib only arm (P=0.47). The combination of ficlatuzumab with gefitinib showed a trend for improved
ORR and PFS in a subgroup of patients with EGFR-sensitizing
mutations and low MET biomarker levels. Preliminary results
suggested improved survival with the combination in patients
with high stromal HGF (P=0.03), but no difference in the overall
population. Paronychia (47%), acne (27%), peripheral edema
(38%), and eczema (17%) were the most common side effects
associated with the combination therapy.81
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TAK701
TAK701 is a humanized anti-HGF monoclonal antibody that
was found to overcome gefitinib resistance in EGFR-mutated
human NSCLC cell lines both in vitro and in xenograft
mouse models.82 A Phase I study with TAK701 in advanced
solid malignancies revealed no specific dose-limiting toxicities, with cough, fatigue, and constipation as the common
adverse events.83

Anti-MET monoclonal antibodies
Onartuzumab
Onartuzumab (MetMAb) is a humanized monovalent monoclonal antibody which binds to the extracellular SEMA domain
of MET. As a result, onartuzumab blocks the binding of the
HGF α-chain to the MET receptor.84 In an orthotopic mouse
xenograft model with KP4 pancreatic cancer cells, onartuzumab inhibited tumor growth, reduced MET phosphorylation
with a concomitant decrease in Ki-67 index, and improved
survival of the mice.85 A Phase I dose-escalation study evaluated single agent onartuzumab and a combination of onartuzumab plus bevacizumab in advanced solid malignancies in
43 patients. The half-life for onartuzumab was 11 days, and no
adverse pharmacokinetic interactions with bevacizumab were
observed. The most common treatment-related adverse events
included fatigue, peripheral edema, and hypoalbuminemia. In
a Phase II study of erlotinib in combination with onartuzumab
in patients with advanced NSCLC after initial therapy, 69
patients were randomized to receive onartuzumab 15 mg/kg
intravenously every 3 weeks in combination with erlotinib 150
mg daily, and 68 patients received placebo intravenously every
3 weeks with erlotinib 150 mg daily. In patients with positive
MET immunohistochemical staining (defined as $50% tumor
cells with moderate or strong staining intensity by immuno
histochemistry [IHC]), the addition of onartuzumab to
erlotinib resulted in a significant improvement in PFS from
1.5 to 2.9 months and median overall survival from 3.8 to
12.6 months.86 A Phase III clinical trial evaluating the combination of erlotinib with onartuzumab in NSCLC (MetLUNG
study) is currently ongoing.87 A Phase II randomized doubleblind, placebo-controlled clinical trial comparing cytotoxic
chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin
(mFOLFOX-6) combined with bevacizumab and placebo to
mFOLFOX-6 with bevacizumab and onartuzumab is also
currently ongoing.88

Biomarkers for MET inhibitors
In the era of targeted agents, it is critically important to
identify biomarkers which predict response to a specific
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class of agents. Although a number of predictive biomarkers to HGF-MET inhibitors are currently being evaluated,
to date none have yet been validated or FDA-approved.
Potential biomarkers explored in clinical trials to predict
response to HGF-MET inhibitors include MET amplification
(MET/Centromere enumeration probe 7 [CEP7] ratio .2
in 200 interphase nuclei), MET translocation, MET mutations, quantitative IHC for total MET or phosphorylated
MET, plasma levels of HGF, and soluble MET receptor. In
preclinical studies with PHA-665752, a MET inhibitor, the
investigators demonstrated that MET amplification was an
excellent predictor of PHA-665752 sensitivity in 41 human
NSCLC cell lines.89 BAY-853474, another specific MET
inhibitor, was able to reduce the tumor burden in glioblastoma, NSCLC, and gastric cancer xenograft models. The
inhibition of MET phosphorylation was dose-dependent,
and the soluble plasma biomarkers HGF, VEGF, and interleukin-8, as well as the MET-ectodomain, could potentially
be used to monitor the response to treatment.38 However,
clinical samples showed only moderately elevated levels of
these biomarkers even with MET amplification.38 This study
supported the use and development of IHC-based analysis
of MET phosphorylation in addition to plasma biomarkers
for monitoring response.
Treatments with ficlatuzumab and rilotumumab have
been shown to result in an increase in plasma total HGF
and soluble MET concentrations from baseline. Elevation
of plasma total HGF and soluble MET concentrations were
reported as pharmacodynamic biomarkers.76,80 In a Phase Ib/II
clinical trial combining rilotumumab with panitumumab
(a human monoclonal antibody to EGFR) for KRAS wildtype metastatic colorectal carcinomas, response rate to the
combination correlated with high cytoplasmic staining
for MET in tumor cells.90 Exploratory biomarker analyses
performed on patients with advanced NSCLC (n=128)
receiving onartuzumab in combination with erlotinib demonstrated an OS benefit in MET-positive patients (n=65),
defined as $50% of tumor cells staining $2+ intensity for
MET by IHC; HR =0.37, P=0.002). A subgroup analysis
suggested IHC analysis of MET expression was a more
sensitive predictor than MET amplification as assessed by
FISH.91 In a multicenter Phase II randomized controlled trial,
MET-expression-positive patients (defined as MET $2+ in
.50% of tumor at IHC) with unresectable hepatocellular
carcinoma showed a significant benefit with tivantinib in the
second-line setting.92 Interestingly, another Phase II trial with
tivantinib demonstrated no obvious relationship of treatment
outcome with biomarkers, including MET gene amplification,
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phospho-MET and HGF expression in tumor, and serum
HGF.93 Recently, the use of gene expression profiling has
allowed for the identification of specific gene signatures
which can be used to classify and predict tumor responses
to targeted agents or chemotherapy. Such signatures are currently being developed and tested for colorectal carcinomas.94
Thus, future clinical trials need to better identify and refine
biomarkers, which will allow for better prediction of response
to MET inhibitors.

Mechanisms of resistance
to HGF-MET inhibitors
Since solid malignancies are comprised of highly
heterogeneous groups of cells, the use of targeted inhibitors may
select a malignant clone of cells, which are inherently resistant
to blockage of the HGF-MET pathway. Acquired resistance in
cancer cells can develop by point mutations, which inhibit the
interaction and/or binding of a molecule to its target receptor.
Another mechanism of acquired resistance is activation of
compensatory signaling pathways or mechanisms, which can
bypass the effects of targeted agents. In a preclinical model,
exposure to MET inhibitors PHA-665752 and PF-2341066 led
to MET resistance through an acquired mutation in the MET
activation loop (Y1230H/C).95 In addition, overexpression of
TGF-α, a ligand for EGFR, resulted in activation of the EGFR
pathway and subsequent resistance to MET inhibitors.95 In
a MET-amplified gastric cancer cell line GTL16, prolonged
exposure to PF-04217903 resulted in 7q32-34 amplification and
overexpression of a novel Staphylococcal Nuclease And Tudor
Domain Containing 1-v-raf murine sarcoma viral oncogene
homolog B (SND1-BRAF) fusion protein. The constitutively
active SND1-BRAF fusion protein resulted in upregulation
and activation of the mitogen-activated protein kinase pathway,
which conferred resistance to MET inhibition.96 After prolonged
exposure to small molecule MET inhibitors, resistant cells developed MET and KRAS amplification. KRAS amplification was
associated with loss of MET dependence and resistance to MET
inhibitors.96 A patient with MET-mutated papillary renal cell carcinoma treated with PF-04217903 was noted to have an acquired
tandem duplication of the mutated MET gene and developed
resistance to PF-04217903-mediated MET inhibition.97 Strategies to overcome HGF-MET resistance would involve targeting
of multiple compensatory pathways simultaneously either by
using multitargeted agents such as cabozantinib (MET, VEGF),
crizotinib (MET, ALK), or by combining targeted agents like
onartuzumab or ficlatuzumab with erlotinib/gefitinib (MET/
HGF and EGFR inhibitors respectively). The use of inhibitors of
heat shock protein 90 (HSP90), a molecular chaperone to MET,
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and a wide range of other key cellular proteins may offer another
approach to overcome resistance to MET inhibition.89,98

Summary
The HGF-MET axis is frequently dysregulated in cancer,
especially in advanced or metastatic disease. Upregulation of
the HGF-MET axis can promote resistance to small molecule
inhibition of several important cellular signaling pathways,
including the EGFR, RAS-RAF-MEK, and Akt-mTOR
pathways. A number of potential predictive biomarkers including MET amplification (MET/CEP7 ratio .2 in 200 interphase
nuclei), MET translocation, MET mutation analysis, quantitative
IHC for total MET and phosphorylated MET, plasma levels of
HGF, and soluble MET receptor, are currently being evaluated
in clinical studies. HGF-MET inhibitors hold promise as novel
molecules that can be used either as monotherapy or as part of
combination therapy with EGFR, RAS-RAF-MEK, and AktmTOR inhibitors in the treatment of various human cancers.
To conclude, in the era of personalized medicine, there is an
increased need to validate biomarkers in specific tumor types to
identify patients who will benefit from HGF-MET inhibitors.
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